Published in final edited form as:

Schizophr Res. 2015 June ; 165(1): 103–107. doi:10.1016/j.schres.2015.03.034.

Increased cardio-metabolic dysfunction in first degree relatives of patients with psychotic disorders

Suraj Sarvode Mothi¹, Neeraj Tandon^{2,3}, Jaya Padmanabhan², Ian T Mathew², Brett Clementz⁶, Carol Tamminga⁷, Godfrey Pearlson^{4,5}, John Sweeney⁷, and Matcheri S Keshavan^{1,*}

¹Psychiatry, Massachussets General Hospital, Boston, MA, USA

²Psychiatry, Harvard Medical School - Beth Israel Deaconess Medical Ctr, Boston, MA, USA

³Baylor College of Medicine, Texas Medical Center, Houston, TX, USA

⁴Olin Neuropsychiatry Research Center, Hartford, CT

⁵Department of Psychiatry and Neurobiology, Yale University, New Haven, CT, USA

⁶Departments of Psychology and Neuroscience, Bio-Imaging Research Center, University of Georgia, Athens GA

⁷Psychiatry, UT Southwestern, Dallas, TX, USA

Abstract

Introduction—Elevated prevalence of comorbid cardio-vascular and metabolic dysfunction (CMD) is consistently reported in patients with severe psychotic disorders such as schizophrenia (SZ), schizoaffective (SZA) and bipolar disorder (BP-P). Since both psychosis and CMD are substantively heritable in nature, we attempted to investigate the occurrence of CMD disorders in first degree relatives of probands with psychosis.

Methods—Our sample included 861 probands with a diagnoses of SZ (n=354), SZA (n=212) and BP-P (n=295), 776 first-degree relatives of probands and 416 healthy controls. Logistic regression was used to compare prevalence of any CMD disorders (diabetes, hypertension, hyperlipidaemia or coronary artery disease) across groups. Post-hoc tests of independence checked for CMD

*Corresponding author. Tel.: +1 617 754 1256; mkeshava@bidmc.harvard.edu.

Contributors Initials of authors: Suraj Sarvode Mothi (SSM), Neeraj Tandon (NT), Jaya Padmanabhan (JP), Ian T. Mathew (ITM), Brett Clementz (BC), Carol Tamminga (CT), Godfrey Pearlson (GP), John Sweeney (JS) and Matcheri S. Keshavan (MSK).

Competing interests: GDP has served on an advisory panel for Bristol-Myers Squibb. JAS has been on advisory boards for Bristol-Myers Squibb, Eli Lilly, P zer, Roche, and Takeda and has received grant support from Janssen. CAT has the following disclosures to make: Intracellular Therapies (ITI, Inc.)—Advisory Board, drug development; PureTech Ventures—Ad Hoc Consultant; Eli Lilly Pharmaceuticals—Ad Hoc Consultant; Sunovion—Ad Hoc Consultant; Astellas—Ad Hoc Consultant; Cypress Bioscience—Ad Hoc Consultant; Merck—Ad Hoc Consultant; International Congress on Schizophrenia Research—Organizer, unpaid volunteer; National Alliance on Mental Illness—Council Member, unpaid volunteer; American Psychiatric Association—Deputy Editor. MSK has received research support from Sunovion and GlaxoSmithKline. Other authors report no disclosures.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

prevalence across psychosis diagnosis (SZ, SZA and BP-P), both in relatives of probands and within probands themselves.

Results—After controlling for potential confounders, first degree relatives with ($p<0.001$) and without ($p=0.03$) Axis I non-psychotic or Axis- II cluster disorders were at a significant risk for CMD compared to controls. No significant difference ($p=0.42$) was observed in prevalence of CMD between relatives of SZ, SZA and BP-P, or between psychosis diagnoses for probands ($p=0.25$).

Discussion—Prevalence of CMD was increased in the first degree relatives of psychosis subjects. This finding suggests the possibility of overlapping genetic contributions to CMD and psychosis. Increased somatic disease burden in relatives of psychotic disorder probands points to need for early detection and preventive efforts in this population.

Keywords

Relatives; Diabetes; Hypertension; Psychotic disorder

1. Introduction

Psychotic disorders such as schizophrenia (SZ), schizoaffective (SZA) and bipolar disorder (BP-P) are increasingly being viewed as ‘multi-system’ conditions, with disease burden extending beyond neurobiological and clinical dimensions (Kirkpatrick, 2009; Leboyer et al., 2012). Somatic comorbidities place patients at high-risk for premature death. Recent reviews show individuals with psychosis are at least 3–4 times more likely than the general population to die due to natural causes (i.e. Medical conditions excluding suicide and accidents) (Brown et al., 2010; Nordentoft et al., 2013). The mortality gap is between 20%–25% compared to the general population (Fleischhacker et al., 2008; Laursen, 2011; Laursen et al., 2014b) and has widened over time with improved treatments and availability of medical services that are less utilized by the severely mentally ill (Saha et al., 2007).

Cardio-vascular and metabolic (hereinafter called cardio-metabolic) disorders (CMD) are known to be the leading medical cause of excess mortality in psychosis (Chwastiak et al., 2006; Laursen et al., 2009; Osborn et al., 2008; Woodhead et al., 2014). This is underscored by statistics reporting a 1.3 to 4.9 fold increase in morbidity and mortality resulting from coronary heart disease, diabetes and treatable risk factors such as hypertension and dyslipidemia (Jeste et al., 1996; Laursen et al., 2014a; McEvoy et al., 2005; Miller et al., 2008; Nordentoft et al., 2013).

A longitudinal analysis (Birkenaes et al., 2007) highlighted identical levels of cardio-metabolic risk factors in SZ and BP-P, with both groups showing twice the prevalence compared to general population. Investigations - both of drug naïve patients with SZ and with BP-P report worse glycemic control compared to healthy controls (Kim et al., 2009; Maina et al., 2008; Regenold et al., 2002; Ryan et al., 2003; Vancampfort et al., 2013). A more recent analysis in a younger first episode sample (mean age, 23.6) from the Recovery After an Initial Schizophrenia Episode (RAISE) study shows cardiometabolic risk factors

and abnormalities are present early in the illness, even before the outset of effects due to antipsychotics (Correll et al., 2014).

Psychotic and cardio-metabolic disorders both have substantive heritability. This raises the question whether cardio-metabolic risk is increased in relatives of people with psychosis. A few family studies have been conducted, albeit in a more narrow focus. Some studies (Fernandez-Egea et al., 2008a; Spelman et al., 2007) show impaired glucose tolerance in first-degree relatives of SZ compared to healthy controls. Two studies detected increased prevalence of diabetes mellitus type-II in first-degree relatives (Fernandez-Egea et al., 2008b; Mukherjee et al., 1989). Another study found associations in a larger sample, but also included second and third degree relatives in the investigation (van Welie et al., 2013). While these studies contribute to our knowledge about the relationship between psychosis and CMD, they were mostly small in sample size and restricted to non-affective psychoses.

Our study sought to confirm and extend results from previous studies by including a large series of probands across the psychosis spectrum (SZ, SZA and BP-P), first-degree non-psychotic relatives of probands, and healthy controls from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) study. As increased CMD abnormalities are well established in psychotic patients, the primary aim of the study was to test the hypothesis that first-degree relatives would have an elevated prevalence of CMD disorders compared to the healthy controls.

2. Methods

2.1 Participants

Our subject pool consisted of individuals recruited as part of the B-SNIP study, a multisite collaborative research consortium (Baltimore, Chicago, Dallas, Detroit, Boston and Hartford). Sites used identical diagnostic and clinical assessment techniques, and shared approaches to recruitment (Tamminga et al., 2013). All sites recruited 1) SZ, SZA, and BP-P probands; 2) first-degree relatives of probands; and 3) healthy comparison subjects to define the rates and severity of abnormalities in the patient and relative groups on measures of interest.

2.1.1 Probands—Patients with a history of psychotic symptoms were recruited if they had at least one available first-degree relative 15–65 years of age willing to participate in the study. 861 probands with a diagnosis of SZ (N=354), SZA (N=212) and BP-P (N=295) were included in the study. Diagnosis was determined at consensus diagnostic meetings after review of data gathered using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), (First et al., 2012) information about the proband's medical and psychiatric history obtained from relatives, and available medical charts. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987).

2.1.2 First-degree relatives—First-degree relatives (N=776) of probands were assessed with SCID and the Structured Interview for DSM-IV Personality (SIDP- IV) (Pfohl et al., 1997). Relatives with presence or past history of psychosis were excluded to avoid confound

due to anti-psychotics. For the sake of analysis in the present study, relatives were further stratified based on clinical diagnosis:

1. **Affected family (AF):** The affected group (N=442) was diagnosed with Axis I non-psychotic or Axis- II cluster A (odd or eccentric) or cluster B (dramatic, emotional, or erratic) personality disorders. First degree relatives diagnosed with Axis I psychotic disorders were excluded from this group.
2. **Non-affected family (NAF):** First-degree relatives (N=334) with no history of Axis I or Axis II diagnosis.

2.1.3 Healthy controls—Healthy volunteers (N=416) were recruited through print and electronic media and research registries. Healthy comparison subjects were required to have no personal history of a psychotic disorder or recurrent depression (based on the SCID and consensus review) and no known immediate family history of these disorders.

2.2 Statistical Methods

Group coding and characterization—The event/outcome variable for the analysis was a binary marker of cardio-metabolic dysfunction (CMD). It was assessed across the sample based on self-reported medical history (“1=yes” or “0=no”) or current use of medication/treatment for any of four cardio-metabolic disorders: coronary artery disease, diabetes, hypertension or hyperlipidemia. A subject was considered as CMD+ if reported to have at least one of the above conditions, CMD- if not. Trends in CMD+ frequency across the 4 study-groups (i.e., controls, NAF, AF and Probands) were assessed using the Cochran-armitage trend test. Sample differences across groups were determined by chi-square tests for gender, race and site and kruskal wallis test for mean age.

Socio-economic status—As a socio-economic gradient has been demonstrated related to cardio-vascular and diabetes factors, (Chaturvedi et al., 1998; Kanjilal et al., 2006; Saydah et al., 2013) with both education and income playing important determinants, for our analysis we used the Family Hollingshead Index Score. This was computed by summing the Hollingshead occupation score multiplied by 7 and the Hollingshead education score multiplied by 4; higher score indicates lower social class. The Hollingshead Socio-Economic Status (SES) Score was not available and missing at random in 134 subjects (<10%). It has been shown that properly performed multiple imputations give less biased results compared to traditional complete case analysis (van der Heijden et al., 2006). Therefore, to account for missing values, we used a multivariate normal imputation method. The event variable CMD was used as a predictor variable because multiple imputations with the outcome have been shown to yield more valid results (Moons et al., 2006). Imputation for Hollingshead SES was performed using the Comprehensive R Archive Network (CRAN) package Amelia. One-way ANOVA was used to check the difference in mean family SES across subject groups.

Main analysis—A logistic regression was performed to evaluate the risk of CMD+ occurrence based on subject status (i.e., control, NAF, AF and proband) while controlling for age, sex, race, site and SES differences. A type-1 error rate of 0.05 was applied. Adequacy

of the regression model fit was evaluated using the Hosmer-Lemeshow calibration test (Hosmer et al., 2013). All statistical analysis was performed using the R statistical programming package (Vienna, Austria; 2013, <http://www.R-project.org>, version 2.15.3). As a post-hoc comparison, a test of independence was performed to compare CMD+ prevalence in relatives of SZ, SZA and BP probands to identify if any specific group influenced results. Similar post-hoc tests of independence were performed across diagnostic groups in probands.

3. Results

Analysis of variance revealed a significant difference in age between all groups ($F=27.7$, $p<0.001$), with the AF reporting highest mean age with a 6.6 yrs difference from the youngest group (Probands). Family groups are older as the majority of relative recruited into the study were parents of probands. The distribution of the Family SES score was similar between the groups. The sex and race ratios significantly differed between groups ($p<0.001$).

Prevalence of CMD frequency is shown in Table 2 and Figure 1. On visual inspection of Figure 1, except for coronary artery disease which was not common, all the other conditions (i.e., diabetes, hyperlipidaemia and hypertension) showed an increasing trend in prevalence from controls to relatives to probands. Subsequent testing for a linear trend in CMD frequency resulted in a highly significant trend increasing from controls to probands with the NAF and the AF groups as intermediaries (Cochran-Armitage trend test $X^2=73.1$, $p<0.001$).

After adjusting for age, sex, race, site and SES, overall CMD rates were significantly different from the control population in all study groups. The results are shown in Table 4. For unaffected family the OR=1.6 (95% CI= 1.03, 2.3; $p=0.03$), affected family OR=2.6 (95% CI= 1.55, 3.03; $p<0.001$) and proband OR=4.8 (95% CI=3.48, 6.96; $p<0.001$). Since both age and SES were significant covariates in the model, we evaluated them as modifiers of the effect of participant group (using an interaction term). No significant interactions were observed. A Hosmer-Lemeshow test for the model was not significant ($p=0.379$) indicating good model calibration. Furthermore, the McFadden pseudo R^2 and chi-square statistics both increase with the log functional form indicating that the overall model is superior in terms of model fit in comparison to a model without covariates. Results from post hoc tests comparing prevalence of CMD across diagnostic groups of probands and relatives of SZ, SZA and BP are shown in Table 3. No significant differences in CMD prevalence were observed in relatives ($X^2= 1.73$, $p=0.42$) or probands across diagnostic groups ($X^2= 2.72$, $p=0.25$).

4. Discussion

As predicted, our findings indicate that probands with psychotic disorders are at significantly increased risk for overall cardio-metabolic dysfunction (OR=4.8) compared to healthy controls. The unaffected family group, independent of any psychiatric problems and drug effects, reported 1.6 times the risk compared to healthy controls. This is in agreement with findings from another large sample analysis looking at associations between diabetes

and relatives of patients but was restrictive to non-affective psychosis (van Welie et al., 2013). In comparison, our finding is novel due to the inclusion of multiple diagnostic categories (both affective and non-affective psychosis) and is suggestive of CMD prevalence as trans-diagnostic and not restricted to non-affective psychosis. What is also unique to our findings is that the first-degree relatives diagnosed with Axis I or Axis II non-psychotic disorders had an increased risk for CMD compared to healthy relatives.

Our observations of increased CMD in unaffected relatives points to the possibility that psychosis and CMD may share risk factors that are familial. This vulnerability could be due to common risk factors linking CMD and psychosis, such as common genetic liability, shared environmental factors and epigenetic interactions. Regarding common genetic liability, there is emerging literature regarding shared loci in SZ or bipolar disorder and cardiometabolic disorders (Andreassen et al., 2013; Gough and O'Donovan, 2005; Liu et al., 2013). For example, Liu et al performed a pathway analysis of type 2 diabetes and schizophrenia risk genes, identifying several 'hub proteins', such as GRB2 and PLCG1, which may interact with networks of proteins in both disorders (Liu et al, 2013). Future genetic investigations should continue to explore a possible link between psychosis and CMD risk alleles.

Shared environmental factors could also contribute to the elevated prevalence of CMD among relatives. Similar to psychotic probands, first-degree relatives affected with non-psychotic disorders may also suffer from poor health habits and decreased access to or compliance with medical care. This possibility is further supported by numerous studies demonstrating an association between cardiometabolic risk and depression (Rudisch and Nemeroff, 2003). Environmental factors that could account for the elevated prevalence of CMD among non-affected first-degree relatives are less clear, but could include caretaker burden (Möller-Leimkühler and Wiesheu, 2012; Schulz et al., 1997) or even social network phenomena (Christakis and Fowler, 2007).

Furthermore, studies of relatives of people with psychosis have reported higher emotional, economic and social distress (Caqueo-Urizar et al., 2011; 2009; Perlick et al., 2010; Reinares et al., 2006). The results from our study highlight an additional need to incorporate somatic disease burden in these investigations.

In comparison to past investigations, our inclusion of BP-P patients and their relatives stands apart. When comparing the CMD occurrence between proband groups for relatives, we report no significant differences ($p=0.43$). Our findings here indicate that the familial risk for CMD spreads across the psychosis spectrum and is not restricted to relatives of non-affective psychosis.

Any confounding due to antipsychotic usage in the first-degree relatives can be ruled out, as any family member with a psychosis diagnosis was excluded from the analysis. However, since the affected relatives had a diagnosis of cluster A or cluster B personality disorders, a few of them received antipsychotics, leading to elevated odds for CMD. Our study is reasonably representative of the general population of patients with psychotic disorders, their first degree relatives and healthy controls. By contrast, the van Welie et al study (van

Welie et al., 2013) had a much higher mean age (62.5) and included only a Caucasian population, and Mukherjee et al (Mukherjee et al., 1989) used data from a population registry, and lacked a comparable control group.

The results of this study should be interpreted in the view of the following limitations. First, we could not establish the presence or severity of comorbid metabolic disorders based on laboratory confirmation, and relied on patient self-report and review of medication treatments for comorbid disease status; this could raise the possibility of selective recall bias. With that said, studies have shown that information provided by psychiatric patients about medical diagnoses is reliable, valid, and useful (Bergmann et al., 1998; Linet et al., 1989; Selim et al., 2004). Second, we also could not distinguish between Type 1 and Type 2 Diabetes in the patient population. Third, no data were collected on current tobacco and alcohol use, which are common in schizophrenia and bipolar populations and act as independent risk factors for cardio-metabolic dysfunction. Effects due to substance abuse may be less likely as we excluded participants meeting the DSM-4 criteria for current or recent (within the past month) substance abuse or past dependence within the last 6 months. However, the effects of past substance abuse cannot be ruled out. Fourth, we could not address the influence of BMI on the obtained results, as data on weight and height of the participants were not recorded. Since obesity runs in families, inclusion of BMI data could have increased the explanatory power. Finally, we also could not control for the effects of shared living situation as some probands may live with first-degree relatives, and others may not.

The results from our analysis elucidate that boundaries for disease-burden in psychosis should be re-thought, for the sake of both etiology and disease prognosis. Our findings suggest several lines of future investigation. First, the observed familial association suggests that cardio-metabolic markers (eg. heart rate variability, HbA1C Levels, lipid profile etc) should be explored as potential heritable markers for psychosis. Second, genetic studies should focus on the possible pleiotropic effects of CMD and psychosis risk genes, with the goal of isolating genes that may contribute to elevated prevalence of CMD in psychosis. Finally, our data suggests that the substantive medical morbidity in families of psychosis probands should motivate studies of somatic disease burden and avenues for early detection and preventive efforts not only in patients but in their relatives.

Acknowledgments

The authors thank Dr. Gunvant Thaker, Dr. Melvin McKinnis, and Dr. Nash Boutros for their collaboration in the design and implementation of this study.

Funding: This work was supported in part by National Institute for Mental Health (NIMH) grants MH078113, MH077945, MH077852, MH077851, MH077862, MH072767, and MH083888.

References

Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI, Roddey JC, McEvoy LK, Desikan RS, Dale AM. International Consortium for Blood Pressure GWAS, Diabetes Genetics Replication and Meta-analysis Consortium, Psychiatric Genomics Consortium Schizophrenia Working Group. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with

- cardiovascular-disease risk factors. *Am J Hum Genet.* 2013; 92:197–209. DOI: 10.1016/j.ajhg.2013.01.001 [PubMed: 23375658]
- Bergmann MM, Byers T, Freedman DS, Mokdad A. Validity of selfreported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults. *Am J Epidemiol.* 1998; 147:969–977. [PubMed: 9596475]
- Birkenaes AB, Opjordsmoen S, Brunborg C, Engh JA, Jonsdottir H, Ringen PA, Simonsen C, Vaskinn A, Birkeland KI, Friis S, Sundet K, Andreassen OA. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. *J Clin Psychiatry.* 2007; 68:917–923. [PubMed: 17592917]
- Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. *Br J Psychiatry.* 2010; 196:116–121. DOI: 10.1192/bjp.bp.109.067512 [PubMed: 20118455]
- Caqueo-Urizar A, Gutiérrez-Maldonado J, Ferrer-García M, Peñaloza-Salazar C, Richards-Araya D, Cuadra-Peralta A. Attitudes and burden in relatives of patients with schizophrenia in a middle income country. *BMC Fam Pract.* 2011; 12:101.doi: 10.1186/1471-2296-12-101 [PubMed: 21943329]
- Caqueo-Urizar A, Gutiérrez-Maldonado J, Miranda-Castillo C. Quality of life in caregivers of patients with schizophrenia: a literature review. *Health Qual Life Outcomes.* 2009; 7:84.doi: 10.1186/1477-7525-7-84 [PubMed: 19747384]
- Chaturvedi N, Jarrett J, Shipley MJ, Fuller JH. Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall Study and the WHO Multinational Study of Vascular Disease in Diabetes. *BMJ.* 1998; 316:100–105. DOI: 10.1136/bmj.316.7125.100 [PubMed: 9462313]
- Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. *N Engl J Med.* 2007; 357:370–379. DOI: 10.1056/NEJMs066082 [PubMed: 17652652]
- Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. *Psychiatr Serv.* 2006; 57:1102–1109. DOI: 10.1176/appi.ps.57.8.1102 [PubMed: 16870960]
- Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM. Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study. *JAMA Psychiatry.* 2014; 71:1350–1363. DOI: 10.1001/jamapsychiatry.2014.1314 [PubMed: 25321337]
- Fernandez-Egea E, Bernardo M, Parellada E, Justicia A, Garcia-Rizo C, Esmatjes E, Conget I, Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. *Schizophrenia Research.* 2008a; 103:110–113. DOI: 10.1016/j.schres.2008.04.017 [PubMed: 18514487]
- Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. *Schizophrenia Research.* 2008b; 98:302–306. DOI: 10.1016/j.schres.2007.10.002 [PubMed: 18031995]
- First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version. Administration Booklet. 2012
- Fleischhacker, WW., Cetkovich-Bakmas, M., De Hert, M., HENNEKENS, CH., Lambert, M., Leucht, S., Maj, M., McIntyre, RS., Naber, D., Newcomer, JW., Olfson, M., Osby, U., Sartorius, N., Lieberman, JA. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Presented at the The Journal of clinical psychiatry; 2008. p. 514-519.
- Gough SCL, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? *J Psychopharmacol (Oxford).* 2005; 19:47–55. DOI: 10.1177/0269881105058380 [PubMed: 16280337]
- Hosmer DW Jr, Lemeshow S, Sturdivant RX. Applied logistic regression. 2013
- Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical Comorbidity in Schizophrenia. *Schizophrenia Bulletin.* 1996; 22:413–430. DOI: 10.1093/schbul/22.3.413 [PubMed: 8873293]
- Kanjilal S, Gregg EW, Cheng YJ, Zhang P, Nelson DE, Mensah G, Beckles GLA. Socioeconomic Status and Trends in Disparities in 4 Major Risk Factors for Cardiovascular Disease Among US

- Adults, 1971–2002. Arch Intern Med. 2006; 166:2348–2355. DOI: 10.1001/archinte.166.21.2348 [PubMed: 17130388]
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987; 13:261–276. [PubMed: 3616518]
- Kim B, Kim S, McIntyre RS, Park HJ, Kim SY, Joo YH. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Investig. 2009; 6:78–84. DOI: 10.4306/pi.2009.6.2.78
- Kirkpatrick B. Schizophrenia as A Systemic Disease. Schizophrenia Bulletin 35. 2009; :sbn183–382. DOI: 10.1093/schbul/sbn183
- Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophrenia Research. 2011; 131:101–104. DOI: 10.1016/j.schres.2011.06.008 [PubMed: 21741216]
- Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychological Medicine. 2014a; 44:1625–1637. DOI: 10.1017/S003329171300216X [PubMed: 24246137]
- Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. Arch Gen Psychiatry. 2009; 66:713–720. DOI: 10.1001/archgenpsychiatry.2009.61 [PubMed: 19581562]
- Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014b; 10:425–448. DOI: 10.1146/annurev-clinpsy-032813-153657 [PubMed: 24313570]
- Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ. Can bipolar disorder be viewed as a multi-system inflammatory disease? Journal of Affective Disorders. 2012; 141:1–10. DOI: 10.1016/j.jad.2011.12.049 [PubMed: 22497876]
- Linnet MS, Harlow SD, McLaughlin JK, McCaffrey LD. A comparison of interview data and medical records for previous medical conditions and surgery. Journal of Clinical Epidemiology. 1989; 42:1207–1213. [PubMed: 2585011]
- Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics. 2013; 6(Suppl 1):S17.doi: 10.1186/1755-8794-6-S1-S17 [PubMed: 23369358]
- Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder. Journal of Affective Disorders. 2008; 110:149–155. DOI: 10.1016/j.jad.2007.12.233 [PubMed: 18234351]
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research. 2005; 80:19–32. DOI: 10.1016/j.schres.2005.07.014 [PubMed: 16137860]
- Miller BJ, Paschall CB, Svendsen DP. Mortality and Medical Comorbidity Among Patients With Serious Mental Illness. Focus. 2008; 6:239–245. DOI: 10.1176/appi.ps.53.7.861
- Moons KGM, Donders RART, Stijnen T, Harrell FE. Using the outcome for imputation of missing predictor values was preferred. Journal of Clinical Epidemiology. 2006; 59:1092–1101. DOI: 10.1016/j.jclinepi.2006.01.009 [PubMed: 16980150]
- Möller-Leimkühler AM, Wiesheu A. Caregiver burden in chronic mental illness: the role of patient and caregiver characteristics. Eur Arch Psychiatry Clin Neurosci. 2012; 262:157–166. DOI: 10.1007/s00406-011-0215-5 [PubMed: 21538092]
- Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989; 1:495. [PubMed: 2563862]
- Nordentoft M, Wahlbeck K, Hällgren J, Westman J, Osby U, Alinaghizadeh H, Gissler M, Laursen TM. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS ONE. 2013; 8:e55176.doi: 10.1371/journal.pone.0055176 [PubMed: 23372832]

- Osborn DPJ, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and metaanalysis. *BMC Psychiatry*. 2008; 8:84.doi: 10.1186/1471-244X-8-84 [PubMed: 18817565]
- Perlick DA, Miklowitz DJ, Lopez N, Chou J, Calvin C, Adzhishvili V, Aronson A. Family-focused treatment for caregivers of patients with bipolar disorder. *Bipolar Disord*. 2010; 12:627–637. DOI: 10.1111/j.1399-5618.2010.00852.x [PubMed: 20868461]
- Pfohl B, Blum N, Zimmerman M. Structured interview for DSM-IV personality. 1997
- Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. *Journal of Affective Disorders*. 2002; 70:19–26. [PubMed: 12113916]
- Reinares M, Vieta E, Colom F, Martínez-Arán A, Torrent C, Comes M, Goikolea JM, Benabarre A, Daban C, Sánchez-Moreno J. What really matters to bipolar patients' caregivers: sources of family burden. *Journal of Affective Disorders*. 2006; 94:157–163. DOI: 10.1016/j.jad.2006.04.022 [PubMed: 16737741]
- Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. *Biol Psychiatry*. 2003; 54:227–240. [PubMed: 12893099]
- Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. *Am J Psychiatry*. 2003; 160:284–289. [PubMed: 12562574]
- Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? *Arch Gen Psychiatry*. 2007; 64:1123–1131. DOI: 10.1001/archpsyc.64.10.1123 [PubMed: 17909124]
- Saydah SH, Imperatore G, Beckles GL. Socioeconomic status and mortality: contribution of health care access and psychological distress among U.S. adults with diagnosed diabetes. *Diabetes Care*. 2013; 36:49–55. DOI: 10.2337/dc11-1864 [PubMed: 22933434]
- Schulz R, Newsom J, Mittelman M, Burton L, Hirsch C, Jackson S. Health effects of caregiving: the caregiver health effects study: an ancillary study of the Cardiovascular Health Study. *Ann Behav Med*. 1997; 19:110–116. [PubMed: 9603685]
- Selim AJ, Fincke G, Ren XS, Lee A, Rogers WH, Miller DR, Skinner KM, Linzer M, Kazis LE. Comorbidity assessments based on patient report: results from the Veterans Health Study. *J Ambul Care Manage*. 2004; 27:281–295. [PubMed: 15287217]
- Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. *Diabetic Medicine*. 2007; 24:481–485. DOI: 10.1111/j.1464-5491.2007.02092.x [PubMed: 17381506]
- Tamminga CA, Ivleva EI, Keshavan MS, Pearlson GD, Clementz BA, Witte B, Morris DW, Bishop J, Thaker GK, Sweeney JA. Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). *Am J Psychiatry*. 2013; 170:1263–1274. DOI: 10.1176/appi.ajp.2013.12101339 [PubMed: 23846857]
- van der Heijden GJMG, Donders TAR, Stijnen T, Moons KGM. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. *Journal of Clinical Epidemiology*. 2006; 59:1102–1109. DOI: 10.1016/j.jclinepi.2006.01.015 [PubMed: 16980151]
- van Welie H, Derks EM, Verweij KH, de Valk HW, Kahn RS, Cahn W. The prevalence of diabetes mellitus is increased in relatives of patients with a non-affective psychotic disorder. *Schizophrenia Research*. 2013; 143:354–357. DOI: 10.1016/j.schres.2012.11.011 [PubMed: 23245702]
- Vancampfort D, Wampers M, Mitchell AJ, Correll CU, Herdt A, Probst M, Hert M. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. *World Psychiatry*. 2013; 12:240–250. DOI: 10.1002/wps.20069 [PubMed: 24096790]
- Woodhead C, Ashworth M, Schofield P, Henderson M. Patterns of physical co-/multi-morbidity among patients with serious mental illness: a London borough-based cross-sectional study. *BMC Fam Pract*. 2014; 15:117.doi: 10.1186/1471-2296-15-117 [PubMed: 24919453]

Figure 1.

Point prevalence of CMD conditions across groups

*Figure not adjusted for age effects

NAF = First-degree relatives with no history of Axis I or Axis- II disorders.

AF= First-degree relatives with Axis I or Axis- II disorders.

Table 1

Demographic characteristics of controls, Non-affected first-degree relatives (NAF), Affected first-degree relatives (AF) and probands.

Variable	Controls (N=416)		NAF* (N=334)		AF# (N=442)		Probands (N=861)		p
	N	%	N	%	N	%	N	%	
Sex(M)	190	46	100	30	137	31	430	50	<0.001
Race [†]									<0.001
AA	122	29	94	28	116	26	310	36	
CA	256	62	217	65	310	70	492	57	
OT	38	9	23	7	16	4	59	7	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	p
Age	37.15	12.69	41.09	16.6	42.75	14.99	36.1	12.52	<0.001
Family SES	39.76	14.35	42.66	14.31	41.49	14.78	41.512	14.81	0.052

[†] AA= African-American, CA=Caucasian & OT=Others

* NAF = First-degree relatives with no history of Axis I or Axis-II disorders.

AF= First-degree relatives with Axis I or Axis-II disorders.

Table 2

Frequency of Cardio-metabolic dysfunction (CMD+)

	Controls (N=416)		NAF (N=334)		AF (N=442)		Probands (N=861)		χ^2	p*
	N	%	N	%	N	%	N	%		
Coronary artery disease	2	0.5%	9	2.7%	16	3.6%	7	0.8%	0.0196	0.8
Diabetes	8	1.9%	19	5.7%	37	8.4%	106	12.3%	43.3	<0.01
Hyperlipidaemia	30	7.2%	40	12%	68	15.4%	168	19.5%	36.1	<0.01
Hypertension	34	8.2%	49	14.7%	93	21%	192	22.3%	40.6	<0.01
Event of CMD(Presence of at least 1 of the above conditions)										
CMD+	57	13.7%	87	26%	141	31.9%	318	36.9%	73.1	<0.01
CMD-	359	86.3%	247	74%	301	68.1%	543	63.1%	-	-

* Cochran-Armitage trend test at 0.05 alpha

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Frequency of Cardio-metabolic dysfunction across probands and relatives of SZ, SZA and BP.

Table 3

		BP		SZA		SZ		X ²	p
Relatives	CMD+	76	27%	56	29%	96	32%	1.73	0.42
	CMD-	206	73%	137	71%	205	68%		
Probands	CMD+	99	34%	78	37%	141	40%	2.72	0.25
	CMD-	196	66%	134	63%	213	60%		

Adjusted odds ratio and 95% Confidence Interval estimates predicting likelihood of CMD occurrence by subject status.

Table 4

	N	OR*	95% CI	p
Controls	416	1.0	--	--
NAF	334	1.6	1.03 2.3	0.03
AF	442	2.6	1.55 3.03	<0.01
Probands	861	4.8	3.48 6.96	<0.01

* Adjusted for age, sex, race and SES